Scribe Therapeutics (SCTX) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$2.62

Estimate

-$3.72

Surprise

+29.5%

Revenue (period 2026-06-30)

$1.9M

Score today

4.9/10

Revenue source: xbrl.

Scribe Therapeutics (SCTX) reported a narrower loss than forecast — diluted EPS of -$2.62 against the -$3.72 estimate (a 29.5% beat on a still-unprofitable quarter).

• HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target — benzinga, 2026-09-03
• Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate — benzinga, 2026-09-02
• Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday — benzinga, 2026-09-02

TrendMatrix currently rates SCTX Sell at 4.9/10; no pre/post engine snapshot brackets this report.

1 of the last 1 quarters beat the estimate; this quarter's +29.5% surprise compares with a +29.5% four-quarter average. Next scheduled report: 2026-11-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$30.15

Price target

$48.45

Stop

$27.36

Upside to target

+60.7%

Reward-to-risk

4.3:1

Model outputs from TrendMatrix’s engine as of 2026-09-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$563.0M

P/E (fwd)

-8.2

52-week range

$17.31–$39.60

Off 52-week high

23.9%

RSI (14)

33

Volume vs avg

0.57×

Score today

4.9/10